Biondvax Pharmaceuticals Long Term Debt

Biondvax Pharmaceuticals (BVXV) currently reports a long-term debt of $24M as of June 2023. That compares with $57M in the prior-year period — down 57.9% year over year. Use the charts on this page to explore Biondvax Pharmaceuticals's long-term debt history and peer comparisons.

Biondvax Pharmaceuticals's long-term debt decreased from $57M to $24M — a 57.9% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Biondvax Pharmaceuticals reported $24M in long-term debt as of June 2023. That compares with $57M in the prior-year period — down 57.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $24M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Biondvax Pharmaceuticals, and consider following BVXV for alerts when major investors trade the stock.

Biondvax Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $24M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BVXV with unrelated industries.